## Nieves Pizarro Lozano

## List of Publications by Citations

Source: https://exaly.com/author-pdf/8460193/nieves-pizarro-lozano-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40 1,299 17 36 g-index

41 1,448 4 3.56 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
40	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 137-44	3.2	324
39	3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 300, 236-44	4.7	125
38	Pharmacology of MDMA in humans. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 914, 225-37	6.5	115
37	Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. <i>Journal of Analytical Toxicology</i> , <b>2002</b> , 26, 157-65	2.9	88
36	3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. <i>Chemical Research in Toxicology</i> , <b>2001</b> , 14, 1203-8	4	81
35	Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. <i>PLoS ONE</i> , <b>2011</b> , 6, e19527	3.7	74
34	Dose-dependent metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. <i>Pharmacological Research</i> , <b>2013</b> , 77, 47-56	10.2	46
33	Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. <i>Biomedical Applications</i> , <b>1999</b> , 723, 221-32		45
32	Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). <i>Drug Metabolism and Disposition</i> , <b>2004</b> , 32, 1001-7	4	43
31	MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. <i>European Journal of Clinical Pharmacology</i> , <b>2005</b> , 61, 551-4	2.8	42
30	Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1448-55	4	27
29	Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites. <i>Bioorganic and Medicinal Chemistry</i> , <b>2002</b> , 10, 1085-92	3.4	27
28	Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2003</b> , 17, 330-6	2.2	27
27	Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2009</b> , 329, 1006-15	4.7	22
26	Pharmacokinetic Comparison of Soy Isoflavone Extracts in Human Plasma. <i>Journal of Agricultural and Food Chemistry</i> , <b>2015</b> , 63, 6946-53	5.7	21
25	Quantification of amphetamine plasma concentrations by gas chromatography coupled to mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1999</b> , 21, 739-47	3.5	20
24	Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	20

## (2021-2002)

23	High-performance liquid chromatography with electrochemical detection applied to the analysis of 3,4-dihydroxymethamphetamine in human plasma and urine. <i>Journal of Chromatography B:</i> Analytical Technologies in the Biomedical and Life Sciences, <b>2002</b> , 769, 313-21	3.2	16	
22	Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome. <i>Neurobiology of Disease</i> , <b>2019</b> , 125, 92-106	7.5	14	
21	Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases. <i>World Allergy Organization Journal</i> , <b>2021</b> , 14, 100498	5.2	14	
20	Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): synthesis, isolation, and characterization of diastereoisomers. <i>Chemical Research in Toxicology</i> , <b>2008</b> , 21, 2272-9	4	12	
19	Improving liquid chromatography-tandem mass spectrometry determination of polycarboxylic acids in human urine by chemical derivatization. Comparison of o-benzyl hydroxylamine and 2-picolyl amine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 164, 382-394	3.5	12	
18	MDMA-induced indifference to negative sounds is mediated by the 5-HT receptor. <i>Psychopharmacology</i> , <b>2018</b> , 235, 481-490	4.7	11	
17	3,4-methylenedioxymethamphetamine induces gene expression changes in rats related to serotonergic and dopaminergic systems, but not to neurotoxicity. <i>Neurotoxicity Research</i> , <b>2014</b> , 25, 161	<b>-4</b> ·3	11	
16	Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. <i>International Archives of Allergy and Immunology</i> , <b>2021</b> , 182, 324-338	3.7	11	
15	Long-lasting neuroprotective effect of sildenafil against 3,4-methylenedioxymethamphetamine-induced 5-hydroxytryptamine deficits in the rat brain. <i>Journal of Neuroscience Research</i> , <b>2012</b> , 90, 518-2	8 <sup>4·4</sup>	10	
14	MDMA-Induced Dissociative State not Mediated by the 5-HT Receptor. <i>Frontiers in Pharmacology</i> , <b>2017</b> , 8, 455	5.6	9	
13	Spices to Control COVID-19 Symptoms: Yes, but Not Only [International Archives of Allergy and Immunology, <b>2021</b> , 182, 489-495	3.7	8	
12	The effect of tea consumption on the steroid profile. <i>Drug Testing and Analysis</i> , <b>2018</b> , 10, 1438-1447	3.5	5	
11	Prevention of cognitive decline in subjective cognitive decline APOE A carriers after EGCG and a multimodal intervention (PENSA): Study design. <i>Alzheimers and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12155	6	4	
10	Soy Isoflavone Extract Does Not Increase the Intoxicating Effects of Acute Alcohol Ingestion in Human Volunteers. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 131	5.6	3	
9	Determination of up to twenty carboxylic acid containing compounds in clinically relevant matrices by o-benzylhydroxylamine derivatization and liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2022, 208, 114450	3.5	3	
8	Potential association of plasma lysophosphatidic acid (LPA) species with cognitive impairment in abstinent alcohol use disorders outpatients. <i>Scientific Reports</i> , <b>2020</b> , 10, 17163	4.9	3	
7	Inter-relationship of the Intestinal Microbiome, Diet, and Mental Health. <i>Current Behavioral Neuroscience Reports</i> , <b>2018</b> , 5, 1-12	1.7	2	
6	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimers Disease, <b>2021</b> , 79, 1015-1021	4.3	2	

5	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. <i>Psychopharmacology</i> , <b>2018</b> , 235, 709-717	4.7	2
4	Sex-Specific Effects of Synbiotic Exposure in Mice on Addictive-Like Behavioral Alterations Induced by Chronic Alcohol Intake Are Associated With Changes in Specific Gut Bacterial Taxa and Brain Tryptophan Metabolism <i>Frontiers in Nutrition</i> , <b>2021</b> , 8, 750333	6.2	O
3	Sex Differences in Plasma Lysophosphatidic Acid Species in Patients with Alcohol and Cocaine Use Disorders. <i>Brain Sciences</i> , <b>2022</b> , 12, 588	3.4	0
2	Use of the Medtep digital health platform in the framework of a multimodal intervention in patients with subjective cognitive decline (PENSA Study). <i>Alzheimers</i> and <i>Dementia</i> , <b>2020</b> , 16, e040447	1.2	
1	A co-creation approach to design the implementation of a multimodal intervention in patients with subjective cognitive decline (PENSA study). <i>Alzheimerss and Dementia</i> , <b>2020</b> , 16, e042998	1.2	